{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-000883","form_type":"8-K","ticker":"INCY","cik":"0000879169","company_name":"INCYTE CORP","filed_at":"2022-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:10.129363+00:00","generated_at":"2026-06-27T10:24:35.082817+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Incyte Q4 product/royalty rev $813M (+20%); non-GAAP EPS $0.10; 2022 Jakafi guidance $2.3-2.4B","bullets":["Jakafi net product revenues $592M in Q4 (+15%) and $2.135B for FY21 (+10%).","GAAP net income $563.9M includes $569M tax benefit from valuation allowance release; non-GAAP diluted EPS $0.10.","Opzelura launch: ~19,000 patients treated in Q4; vitiligo sNDA under Priority Review with PDUFA April 18, 2022.","Parsaclisib NDA withdrawn for FL/MZL/MCL in U.S.; baricitinib SLE Phase 3 discontinued; baricitinib AD sNDA faces potential CRL.","2022 guidance: Jakafi $2.3-2.4B, other heme/onc $210-240M; GAAP R&D $1.55-1.59B, SG&A $950M-1B."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-000883","json":"https://secwatch.observer/filing/0001558370-22-000883.json","markdown":"https://secwatch.observer/filing/0001558370-22-000883.md","text":"https://secwatch.observer/filing/0001558370-22-000883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/0001558370-22-000883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879169/000155837022000883/incy-20220208x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T10:24:35.082817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}